New Clinical Trials Test Baricitinib to Preserve Insulin-Producing Cells in Type 1 Diabetes

Today, insulin is the only available treatment for Type 1 diabetes. But researchers have long sought therapies that could do more—drugs that might prevent, delay, or reverse the autoimmune attack that destroys insulin-producing beta cells in the first place.

Baricitinib represents one promising approach. This small-molecule drug blocks a protein called Janus Kinase (JAK), which plays a critical role in immune cell signaling. By modulating these pathways, baricitinib may help protect the remaining beta cells that are still functioning early in Type 1 diabetes.

A Phase 2 clinical trial funded by Breakthrough T1D, conducted in Australia and published in the New England Journal of Medicine, demonstrated that baricitinib could extend the 'honeymoon period'—the window of time after diagnosis when the pancreas still produces some of its own insulin.

Researchers found that the drug helped preserve beta cell function in newly diagnosed individuals with Type 1 diabetes. The more insulin-producing cells that remain functional, the better blood sugar management becomes and the fewer long-term complications may develop.

Based on these encouraging Phase 2 results, Eli Lilly and Company is now launching two new Phase 3 clinical trials. These larger, international studies will test whether the benefits observed in the earlier trial hold up across a broader population and in diverse geographic locations.

The trials include recruiting sites in Canada, alongside locations in other countries. Phase 3 trials are a critical step—they confirm whether a therapy works in real-world conditions and gather additional safety data before potential regulatory approval.

A disease-modifying therapy that preserves beta cell function could change the treatment landscape for newly diagnosed individuals. Rather than relying solely on insulin injections or pumps, patients might benefit from a drug that slows or halts the underlying autoimmune process.

If baricitinib proves effective, it could offer people with Type 1 diabetes better blood sugar control with potentially fewer insulin injections, less hypoglycemia, and reduced risk of long-term complications. The Phase 3 trials will help determine whether this potential can be realized.

Origin: breakthrought1d.ca (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.